A study to investigate the pharmacokinetics of AZD2389 in healthy participants when administered alone and in combination with quinidine

Exclusion Criteria

• - History of any clinically important disease or disorder.
• - History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Any clinically important abnormalities in hematology, clinical chemistry, urinalysis, coagulation results or other laboratory values and vital signs.
• - Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV).
• - Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.
• - Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
• - Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to screening.
• - Positive screen for drugs of abuse, or alcohol or cotinine at Screening.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
• - History of hypersensitivity to dipeptidyl peptidase 4 (DPP4) inhibitors.